Clinical trials: Acute Cardiac Syndrome
Acute Coronary Syndrome
Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque
The purpose of this study is to determine whether intensive lipid lowering and Omega-3 fatty acid are effective in the treatment of coronary atherosclerotic plaque.
- Trial name
- NCT00760786
- Testing
- Intensive lipid lowering plus Omega3-fatty acid, Moderate lipid lowering plus Omega3-fatty acid
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome, Acute Coronary Syndrome With Renal Dysfunction
Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction
The project is planed to explore the impact of LTBP4 and other matrix protein and potentially related biomarkers on renal outcomes, cardiac outcomes and all-cause mortality in patients with suspected acute coronary syndrome (ACS).
- Trial name
- NCT04998227
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Coronavirus, SARS-CoV-2
Hemodynamic Characteristics of Patients With SARS-CoV-2
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern.
- Conditions
- Coronavirus, SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- PiCCOVID (NCT04337983)
- Testing
- Transpulmonary thermodilution, Echocardiography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Bicetre Hospital
Heart Diseases, Depression
COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients
The specific aim of the "Coronary Patients Evaluation Study" (COPES) Project 2 is, within a Phase-I RCT, to examine patient satisfaction, treatment safety, and symptom reduction associated with treatment for symptoms of distress…
- Trial name
- NCT00158054
- Testing
- Enhanced depression care, Referred depression care
- Where
- 3 sites in United States
- Volunteers
- 157 people
- Sponsor
- Columbia University
Acute Coronary Syndrome
Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography
The purpose of the trial is to evaluate the completeness of struts coverage and vessel wall response (strut malapposition, neoin-timal formation) to the bio-active-stent (BAS) versus ever-olimus-eluting stent (EES) implanted for…
- Trial name
- BASE-OCT (NCT01080859)
- Testing
- OCT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- The Hospital District of Satakunta
Cardiogenic Shock
Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock
Cardiogenic shock (CGS) affects up to 10% of patients suffering acute coronary syndrome. It has a 30 day mortality of 45-50%. No pharmacological nor intervention/device trials have had any impact on this mortality in the last 20…
- Trial name
- EUROSHOCK (NCT03813134)
- Testing
- Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO
- Where
- 47 sites in Austria, Belgium and 6 more
- Volunteers
- 428 people
- Sponsor
- University of Leicester
Chest Pain, Acute Coronary Syndrome
Analysis Between Coronary Angiotomography and Sensitive Troponin in Intermediate Risk of Acute Coronary Syndrome
In recent years, a large number of studies have been conducted on how to improve the treatment of patients in the Emergency Room (ER) complaining of chest pains.
- Trial name
- CONECTTIN (NCT02772991)
- Testing
- troponin measurement
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo General Hospital
Bicuspid Aortic Valve, Thoracic Aortic Aneurysm
Assessment of Risk in Thoracic Aortopathy Using 18F-Sodium Fluoride
Patients with bicuspid aortic valve-related aortopathy are at increased risk of aortic dilatation, dissection and rupture. Currently, risk stratification is largely based on aortic diameter measurements, with those deemed high…
- Conditions
- Bicuspid Aortic Valve, Thoracic Aortic Aneurysm, Aortic Dissection
- Trial name
- AoRTAS (NCT04083118)
- Testing
- clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI, Repeat 18F sodium fluoride PET/MRI
- Where
- United Kingdom
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Acute Kidney Injury, Kidney Failure Chronic
French AKI Registry (FAKIR): A Multicenter Study on the In-Hospital Management and Outcomes of Severe Acute Kidney Injury in Nephrology Units
Acute Kidney Injury (AKI) is a common and serious condition in hospitalized patients, especially when it reaches stages 2 or 3 according to the KDIGO classification.
- Conditions
- Acute Kidney Injury, Kidney Failure Chronic, Cardiorenal Syndrome, Renal Replacement Therapies
- Trial name
- FAKIR (NCT07123324)
- Volunteers
- 750 people
- Sponsor
- University Hospital, Strasbourg, France
Circulatory Shock, Sepsis
Shock and Acute Conditions OutcOmes Platform
In-hospital mortality of patients admitted in the intensive care unit (ICU) for circulatory shock remains high (between 20 and 40%).
- Conditions
- Circulatory Shock, Sepsis, Cardiogenic Shock, Major Trauma
- Trial name
- ShockCO-OP (NCT06376318)
- Testing
- Inotrope, Mechanical circulatory support, anti-bodies
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Saint-Louis Hospital, Paris, France
Acute Coronary Syndrome
Effectiveness of Thrombus Aspiration in Plaque Reduction for Patients With Acute Coronary Syndromes
Although successful, percutaneous coronary interventions (PCI) with stent implantation may be hampered by periprocedural myocardial necrosis.
- Trial name
- REMNANT (NCT01342848)
- Where
- 3 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Raffaele De Caterina
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company
HIV Infection, Coronary Heart Disease
High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV
HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily) in HIV-infected persons taking…
- Trial name
- HILLCLIMBER (NCT02841774)
- Testing
- Pravastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Feinstein
COVID-19 Infection
Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked
To perform comprehensive cardiac and thoracic non invasive imaging assessment by MRI and/or CT scan including cardiac functional evaluation and myocardial tissue characterization of COVID_19 related disease in pediatric patients…
- Trial name
- CARDOVID (NCT04455347)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Imagine Institute
Smoking, Acute Coronary Syndrome
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.
- Trial name
- NCT01170338
- Testing
- Varenicline 100 mg by mouth twice daily, control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Newark Beth Israel Medical Center
Heart Failure
One-year Outcomes of Electromechanical Activation Time (EMAT)-Guided vs. Symptom-guided Heart Failure Therapy in Acute Heart Failure Syndrome (AHFS) Patients
Left ventricular systolic time intervals, including pre-ejection period (PEP), ejection time (ET), and their ratio (PEP/ET), is determined by the systolic and diastolic function and ventriculo-arterial coupling.
- Trial name
- NCT01298232
- Testing
- Cardiophonogram
- Where
- 2 sites in Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Intensive Care Unit Syndrome, Intensive Care Neuropathy
Recovery From ICUAW Following Severe Respiratory and Cardiac Failure
To observe and identify determinants of recovery from intensive care unit-acquired weakness (ICUAW) following a severe cardiorespiratory failure requiring extra-corporeal membrane oxygenation (ECMO).
- Conditions
- Intensive Care Unit Syndrome, Intensive Care Neuropathy, Intensive Care (ICU) Myopathy, Acute Respiratory Distress Syndrome
- Trial name
- CLEVERER (NCT03753412)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Barts & The London NHS Trust
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Coronary Arteriosclerosis, Acute Coronary Syndrome
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking…
- Trial name
- SWAP (NCT00356135)
- Testing
- prasugrel 10 mg, clopidogrel, prasugrel 60 mg
- Where
- 9 sites in United States
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.